Relationship between quinolone use and emergence of ciprofloxacin-resistant Escherichia coli in bloodstream infections - Wikidata - wikimedia - TriplyDB

Relationship between quinolone use and emergence of ciprofloxacin-resistant Escherichia coli in bloodstream infections

Relationship between quinolone use and emergence of ciprofloxacin-resistant Escherichia coli in bloodstream infections

http://www.wikidata.org/entity/Q35111896

about

Inhibition of mutation and combating the evolution of antibiotic resistance Emerging mechanisms of fluoroquinolone resistance Bacterial Responses and Genome Instability Induced by Subinhibitory Concentrations of Antibiotics Posttreatment changes in Escherichia coli antimicrobial susceptibility rates among diarrheic patients treated with ciprofloxacin.In vitro selection of resistance in Escherichia coli and Klebsiella spp. at in vivo fluoroquinolone concentrations Randomised trials of STD treatment for HIV prevention: report of an international workshop. HIV/STD Trials Workshop Group.Risk factors for antibiotic-resistant Escherichia coli isolated from hospitalized patients with urinary tract infections: a prospective study.Emergence and dissemination of quinolone-resistant Escherichia coli in the community.Genetic characterization of highly fluoroquinolone-resistant clinical Escherichia coli strains from China: role of acrR mutations.The magnitude of the association between fluoroquinolone use and quinolone-resistant Escherichia coli and Klebsiella pneumoniae may be lower than previously reported.Efficacy of rifaximin compared with ciprofloxacin for the treatment of acute infectious diarrhea: a randomized controlled multicenter study.Correlation of overexpression of efflux pump genes with antibiotic resistance in Escherichia coli Strains clinically isolated from urinary tract infection patients.Using interrupted time series analysis to assess associations of fluoroquinolone formulary changes with susceptibility of gram-negative pathogens and isolation rates of methicillin-resistant Staphylococcus aureus Molecular epidemiology of fluoroquinolone-resistant Escherichia coli bloodstream isolates from patients admitted to European cancer centers.Emergence of fluoroquinolone-resistant Escherichia coli in fecal flora of cancer patients receiving norfloxacin prophylaxis The clinical impact of fluoroquinolone resistance in patients with E coli bacteremia Mechanisms of and risk factors for fluoroquinolone resistance in clinical Enterococcus faecalis isolates from patients with urinary tract infections.The fluoroquinolones: how long will their utility last?High rate of coadministration of di- or tri-valent cation-containing compounds with oral fluoroquinolones: risk factors and potential implications.Development of a rapid assay for detecting gyrA mutations in Escherichia coli and determination of incidence of gyrA mutations in clinical strains isolated from patients with complicated urinary tract infections.Fluoroquinolone resistance mechanisms in an Escherichia coli isolate, HUE1, without quinolone resistance-determining region mutations A near-fatal case of sepsis with an antibiotic-resistant organism complicating a routine transrectal prostate biopsy in a health care worker.Antibiotic prophylaxis for patients with acute leukemia.Association between antimicrobial consumption and resistance in Escherichia coli.Risk factors and clinical characteristics of patients with qnr-positive Klebsiella pneumoniae bacteraemia.Ciprofloxacin prophylaxis in patients with acute leukemia and granulocytopenia in an area with a high prevalence of ciprofloxacin-resistant Escherichia coli.Trends in antimicrobial susceptibilities among Enterobacteriaceae isolated from hospitalized patients in the United States from 1998 to 2001.In vitro susceptibilities of gram-negative bacteria isolated from hospitalized patients in four European countries, Canada, and the United States in 2000-2001 to expanded-spectrum cephalosporins and comparator antimicrobials: implications for therap Preferential Use of Nitrofurantoin Over Fluoroquinolones for Acute Uncomplicated Cystitis and Outpatient Escherichia coli Resistance in an Integrated Healthcare System.Clinical and microbiological impact of discontinuation of fluoroquinolone prophylaxis in patients with prolonged profound neutropenia.Bacteremia due to quinolone-resistant Escherichia coli in a teaching hospital in South Korea.Epidemiological investigation of fluoroquinolone resistance in infections due to extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae.[How can we protect against broad-band pathogens? The situation with quinolone resistance]Risk factors for community-acquired ciprofloxacin-resistant Escherichia coli urinary tract infection.Hospital and community fluoroquinolone use and resistance in Staphylococcus aureus and Escherichia coli in 17 US hospitals.Clinical epidemiology of ciprofloxacin resistance and its relationship to broad-spectrum cephalosporin resistance in bloodstream infections caused by Enterobacter species.Serious antimicrobial resistance status of pathogens causing hospital-acquired lower respiratory tract infections in North China.Utilization of fluoroquinolones and Escherichia coli resistance in urinary tract infection: inpatients and outpatients.Epidemiology of ciprofloxacin resistance and its relationship to extended-spectrum beta-lactamase production in Klebsiella pneumoniae isolates causing bacteremia.Decreased Invasive Capacity of Quinolone‐ResistantEscherichia coliin Patients with Urinary Tract Infections

P2860

Q21146100-A55E9434-415D-4440-B2CE-CC8C6CF98424 Q24644842-E2CE0192-ED65-4D2D-A098-7344B8C914FA Q27008535-DDE470E8-4C95-41B5-9E25-C6ED854864CD Q33215850-72E83DD4-5F66-4DD5-B77C-2DDD938267AB Q33561341-A601DC97-5685-49FD-A926-B4F492EAB200 Q33936966-BD849EF8-B2F9-41E9-B864-7DFBBEEAAE49 Q33971097-8A15146F-776C-4028-AD37-0B4098DF26FB Q33978075-7A31BD96-E4BE-4D9F-B89A-F9A67D4437AB Q33982113-1D244DCB-6A41-434C-BCA0-6DF88CDAD414 Q34141233-1080A2EA-25EE-4070-90EA-3897023E47E2 Q34206683-8B874EB0-6662-4018-8B73-60208AE47A51 Q34487416-3E6D7294-2FE6-421C-886F-DF91CEEAA0D5 Q34680578-05607F0B-594A-465A-92F8-3560AD899F3E Q35122412-FF9DDB64-0735-4ED0-8923-CFE896D4FF2F Q35122694-AE07387A-F479-4323-92CC-39476B6B8186 Q35164228-8CE3676B-3DAF-4251-8D37-D3BCA70C6EB4 Q35530526-D41BBFC0-1365-462F-BA8C-119194F5978D Q35733987-9918104F-A165-4DA1-8B4C-2C6D67E0E6DB Q36031279-5766D94D-BBB7-4A5B-A178-51B4A96DE6DC Q36546371-2498F898-B9AD-43C7-9381-9438AB575891 Q36871802-860126EA-FFD9-4701-ABF1-D26CED562BF8 Q36947222-3ABA52BA-CCF3-42E3-85AE-B5AD1C1922EC Q37071680-F3BB6215-C28C-4B9D-A3CC-926D73F3E587 Q37115726-CDC657E3-EB75-48F4-B8B8-1B59C324ABE9 Q37286916-5FF4D6CC-5D40-4B5A-A878-C73B74D765C0 Q39220949-B9F1F4A8-E8B8-4BE6-8A00-1061973C2C49 Q39746439-10C2E3E0-62F7-47E0-998E-28E87D627839 Q39913204-56B072DF-27A8-4341-95BF-1504BFB469D2 Q40432811-1DD1A7F9-718F-4960-97C7-C98A129F1F30 Q42218537-FEABD3C3-3EC4-46EF-B986-D9B0191804C7 Q43593616-7255DB1E-AFD4-4F8A-8D78-7CDF67470383 Q43743478-786F27FD-726E-4CBC-8869-6BA14B8E251E Q43986465-3977F55F-A893-4709-A646-428F68085B06 Q44901297-ED871CB0-78C3-4AF9-BE18-1828999405DF Q44912219-E86083A1-655A-4172-80E3-D4AF8FE03798 Q45252185-54BD3963-F014-4B6A-9E56-B0F898BD0BCE Q45934005-2426415E-5C1B-4681-AC82-4FC25BF3BDF9 Q46478579-43E4F43A-C0FC-43AE-AA3B-5D6677D4AA1A Q54058575-5018249E-E7A8-49C7-810C-BA116FD7BD91 Q58387772-B21B933F-B1CF-423F-B64E-5803A60CA997

P2860

Relationship between quinolone use and emergence of ciprofloxacin-resistant Escherichia coli in bloodstream infections

http://www.wikidata.org/entity/Q35111896

description

1995 nî lūn-bûn

@nan

1995 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

1995 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

1995年の論文

@ja

1995年論文

@yue

1995年論文

@zh-hant

1995年論文

@zh-hk

1995年論文

@zh-mo

1995年論文

@zh-tw

1995年论文

@wuu

name

Relationship between quinolone ...... coli in bloodstream infections

@ast

Relationship between quinolone ...... coli in bloodstream infections

@en

type

label

Relationship between quinolone ...... coli in bloodstream infections

@ast

Relationship between quinolone ...... coli in bloodstream infections

@en

prefLabel

Relationship between quinolone ...... coli in bloodstream infections

@ast

Relationship between quinolone ...... coli in bloodstream infections

@en

P1433

Q35111896-94CF6D45-E4B8-4785-ADF0-FE28D3AAEB0A

P1476

Q35111896-033D28EA-51D0-41E0-9875-1A22B082B1A4

P2093

Q35111896-11683C55-98E7-40A1-9E09-EA3BF9E49903

Q35111896-2A94377E-A033-4E47-9401-895B19C96C59

Q35111896-A20A43A4-CAD7-4AF2-87FE-993D27C50D0E

Q35111896-D06A97DA-BCE9-418B-83F1-89E4BE413AEF

P2860

Q35111896-0EAF5588-CCEA-418F-8E26-DE776CADAD03

Q35111896-10D89BBC-9186-4980-9941-B915594929D7

Q35111896-168C7CDD-61E7-4D40-B88A-FFED77596387

Q35111896-193D94CB-E466-4A6D-9CBE-FA4D093B2A48

Q35111896-27E0572E-20F8-4A42-A73A-462292F06003

Q35111896-4C27341A-0D52-4A88-8E08-45B645ABA783

Q35111896-54C955BE-F70C-4DCF-AFA4-B66651990EFE

Q35111896-5E508505-F523-41FD-B90E-EE8E8AA492D3

Q35111896-6AF1FDE5-D2A3-4C90-ABAC-ED08347EFA07

Q35111896-6D318C2B-2480-4280-BFCE-B8FD7F7F7907

P304

Q35111896-2C3877F7-24C4-4A78-BF75-024E8F9CA17B

P31

Q35111896-4E1B849B-CA45-444A-BA0E-77458762FCF9

P356

Q35111896-AD104A71-DDC8-4CF7-8742-416B842E27F9

P407

Q35111896-F575F842-7A39-407C-955D-6C7A8F05B076

P433

Q35111896-024093F8-1255-4159-B6E2-13A5C0D5E60D

P478

Q35111896-1FBAF267-184B-4CA5-A043-CC8FDC4A2471

P50

Q35111896-0BCFA365-E04D-4018-9EFC-18E7B1BF48C8

Q35111896-DC3D3D82-729B-4003-BBDE-FCEA94F53B6B

P577

Q35111896-C3FD0F27-F22C-4E45-98C3-2828BB5D8313

P698

Q35111896-5B3A5A3E-8C85-4A92-88A1-2B1469B5DFED

P921

Q35111896-F9FFE958-7C92-48A6-AA6C-BE5260BC7EAE

P932

Q35111896-F50F7AD5-0A1C-470D-96F4-BB13B0C93121

P356

P1433

Antimicrobial Agents and Chemotherapy

P1476

Relationship between quinolone ...... coli in bloodstream infections

@en

P2093

C Peña

http://www.w3.org/2001/XMLSchema#string

F Tubau

http://www.w3.org/2001/XMLSchema#string

J Ariza

http://www.w3.org/2001/XMLSchema#string

J M Albareda

http://www.w3.org/2001/XMLSchema#string

P2860

Rapid emergence of quinolone resistance in cirrhotic patients treated with norfloxacin to prevent spontaneous bacterial peritonitis

Emergence of fluoroquinolone-resistant Escherichia coli at a cancer center.

Endogenous active efflux of norfloxacin in susceptible Escherichia coli

Development of resistance to nalidixic acid and the fluoroquinolones after the introduction of norfloxacin and ofloxacin

Characterization of fluoroquinolone-resistant mutants of escherichia coli selected in vitro.

Association with prior fluoroquinolone therapy of widespread ciprofloxacin resistance among gram-negative isolates in a Veterans Affairs medical center.

Resistance to quinolones in gram-negative microorganisms: mechanisms and prevention.

Mechanisms of action of and resistance to ciprofloxacin.

In vitro emergence of quinolone-resistant mutants of Escherichia coli, Enterobacter cloacae, and Serratia marcescens.

Routes of quinolone permeation in Escherichia coli

P304

520-524

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/AAC.39.2.520

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

39

http://www.w3.org/2001/XMLSchema#string

P50

P577

1995-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

7726525

http://www.w3.org/2001/XMLSchema#string

P921

P932

162571

http://www.w3.org/2001/XMLSchema#string